News and Announcements
Proteomics International Laboratories Interim Financial Report
- Published February 26, 2016 4:58PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th February 2016, ASX Announcement
Proteomics International Laboratories Limited (PILL) is a life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteings. The Company’s business model operates from a proprietary proteomics-based technology platform in three synergistic areas: Diagnostics, Analytical services and Therapeutic drug discovery.
During the half-year PILL focused on the commercialisation of PromarkerD, the world’s first proteomics-derived predictive (prognostic) test for the diagnosis of Diabetic Kidney Disease. PILL is pursuing the commercial adoption of PromarkerD as a Laboratory Developed Test (LDT), standard clinical pathology In vitro Diagnostic Test (IVD) and Companion Diagnostic (CDx). Partnering and licensing discussions with major pharmaceutical and health care companies for PromarkerD were ongoing, and PILL has now established commercialisation discussions in three major health care markets – USA, China and Japan. Discussions will continue to be advanced in the coming reporting period.
To read the full announcement, please click here.